EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSPLAG00000022535
Gene Symbol: CACNA1A
3 Cross references
186 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSPLAG00000023477
Gene Symbol: CACNA1B
4 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSPLAG00000009521
Gene Symbol: CACNA1D
4 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSPLAG00000012504
Gene Symbol: CACNA1E
2 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSPLAG00000009672
Gene Symbol: CACNA1E
3 Cross references
206 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSPLAG00000002894
Gene Symbol: CACNA1G
3 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSPLAG00000011803
Gene Symbol: CACNA1I
2 Cross references
183 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSPLAG00000020012
Gene Symbol: CACNA1S
3 Cross references
198 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSPLAG00000019414
Gene Symbol: CNR1
1 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSPLAG00000015747
Gene Symbol: CNR1
2 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 2-Like

Ensembl ID : ENSPLAG00000022750
Gene Symbol: LOC106948717
3 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSPLAG00000007133
Gene Symbol: CA12
1 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).